Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Calendar
Upcoming events
01Jun
Annual General Meeting 2026
25Jun
Hansa Biopharma Capital Markets Day
16Jul
Interim Report for January-June 2026
Press releases
Our latest press releases
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Regulatory press release
19/05/2026
Hansa Biopharma participating at LSX Nordic Congress
18/05/2026
Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
12/05/2026
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Regulatory press release
28/04/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
